> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/fgfr1-amplification-in-er+-breast-cancer.md). # FGFR1 Amplification in ER+ Breast Cancer FGFR1 amplification is one of the clearest bypass pathways in **ER-positive, HER2-negative breast cancer**. It shows up most often in more aggressive **luminal-B-like** disease. ### What FGFR1 amplification means **FGFR1** stands for **fibroblast growth factor receptor 1**. It is a cell-surface receptor that receives growth signals and then activates downstream pathways such as **MAPK/ERK** and **PI3K/AKT**. When a report says **FGFR1 amplification**, it means the tumour carries extra copies of the **FGFR1** gene. That extra copy number can increase signalling for: * growth * survival * migration * endocrine resistance In breast cancer, FGFR1 amplification is reported in roughly **7.5% to 17%** of cases overall. It is enriched in more aggressive **ER-positive luminal-B-like tumours**. ### FGFR1 is a well-described resistance mechanism. In ER-positive disease, FGFR1 amplification has been associated with: * earlier relapse * weaker response to endocrine therapy * persistence of estrogen-receptor signalling even when estrogen is suppressed One reason is pathway cross-talk. FGFR1 can keep survival and proliferation signalling active even when the main endocrine pathway is under pressure. That helps explain why some ER-positive cancers keep growing despite aromatase inhibition or other endocrine strategies. ### Why a Guardant360 FGFR1 result can appear, fade, or disappear A **Guardant360** result reflects **circulating tumour DNA** in the blood. It does not sample every tumour cell in the body at the same moment. That matters more for **copy-number signals** like FGFR1 amplification than for some simple point mutations. A strong FGFR1 call on one draw can look weaker later, or disappear from a later report, for a few common reasons: * **Lower tumour burden** can reduce ctDNA shedding below the reporting threshold. * **Clonal shifts** can make a different tumour population dominate the blood signal. * **Detection cutoffs** can move a result from high to low to not reported without proving the biology is gone. A disappearing ctDNA FGFR1 call does **not** prove that the tumour permanently reverted. It also does **not** mean the earlier call was meaningless. Most often, it means the currently shedding tumour population is no longer producing a strong enough copy-number signal to be called on that blood draw. For closely related context, see [Blood Biopsy Trial — Getting Ahead of Treatment Resistance](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/blood-biopsy-trial-getting-ahead-of-treatment-resistance.md). For cross-subtype context on low shedding and negative blood-test results, see [ctDNA and cfDNA in Breast Cancer: What “Low Shedding” Means](/myhealingcommunity-docs/breast-cancer/ctdna-and-cfdna-in-breast-cancer-what-low-shedding-means.md). ### Is FGFR1 targetable today? Biologically, yes. In routine breast-cancer care, not yet in the same way as **ESR1**, **PIK3CA**, **HER2**, or **BRCA-related** pathways. That means two statements can both be true: * there is **no routine FGFR1-directed standard of care** in breast cancer today * FGFR1 is still a **real trial target** and a meaningful resistance mechanism Clinical research has explored: * **pan-FGFR inhibitors** * **FGFR-selective agents** * newer **FGFR1/2 degraders** * combination strategies with **endocrine therapy** and **CDK4/6 inhibition** So FGFR1 is best treated as a **research-active target**, not a solved clinical target. ### Where FGFR1 fits in the EMT and fibrosis axis FGFR1 is not itself a classic fibrotic factor. It still feeds many of the same downstream programmes that drive **EMT**, stromal remodelling, invasion, and treatment escape. **Important overlap points include:** * **TGF-beta/SMAD** signalling * **YAP1/TAZ** mechanosensing and matrix-stiffness responses * **CTNNB1 / beta-catenin** signalling * **TWIST1** and **VIM**-linked mesenchymal shift * **EZH2** and **LSD1/KDM1A**-linked epigenetic locking of resistant states That overlap helps explain why **FGFR1-amplified disease** can also look biologically aligned with the same EMT and fibrosis nodes often discussed in resistant ER-positive disease. This convergence is especially well described around [TGF-beta, WNT, and YAP/TAZ](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2015.00059/full), the [YAP/TAZ fibrosis-cancer bridge](https://pmc.ncbi.nlm.nih.gov/articles/PMC6274979/), [SMAD3-driven fibrotic signalling](https://www.ijbs.com/v18p2795.htm), and the broader biology of the [fibrotic tumour stroma](https://www.jci.org/articles/view/93554). {% hint style="info" %} This page stays focused on **ER-positive breast cancer**. For the broader cross-cancer framing of very hard, stiff, or “cement-like” lesions, including the three-layer model of driver programme, fibrotic scaffold, and fibrin/perfusion, see [Fibrotic, Hard or “Cement‑Like” Lesions](/myhealingcommunity-docs/fibrotic-hard-or-cement-like-lesions.md). {% endhint %} ### Adjuncts No supplement has been shown to reliably **erase FGFR1 amplification** in patients. **Some options may have plausible downstream relevance to the FGFR1-EMT-fibrosis axis, but they are still experimental and supportive rather than proven FGFR1-directed treatments.** ### Losartan Losartan as an anti‑fibrotic adjuvant\ Losartan, an angiotensin II receptor blocker, has been studied as a way to remodel stiff, fibrotic tumour stroma by inhibiting TGF‑beta‑driven collagen deposition, reducing solid stress, and improving perfusion and drug delivery. This has been explored in preclinical and modelling work in breast and pancreatic cancer and fits into Layer 2 (fibrotic scaffold) and Layer 3 (perfusion) of the hard‑lesion picture. It does not target FGFR1 directly, but it may help soften some of the mechanical barriers that FGFR1‑driven biology builds. ### Melatonin Melatonin may affect endocrine signalling, oxidative stress, EMT, and some important FGFR-linked downstream pathways. That makes it **mechanistically very interesting**. It does **not** make it a proven treatment for FGFR1 amplification. A recent paper by **Doris Loh and colleagues** proposes that melatonin may disrupt oncogenic phase separation by changing redox conditions, multivalent interactions, and intracellular electrochemical micro-environments. **In the 2026 paper by Loh et al.,** [***Multiaxial Biophysical Control of Oncogenic Phase Separation by Indoleamines***](https://www.biorxiv.org/content/10.64898/2026.02.03.703596v1), melatonin is discussed as a possible regulator of multiple condensate‑linked oncogenic hubs, including EMT and fibrotic drivers such as SMAD3, CTNNB1, YAP1/TAZ, TWIST1, VIM, EZH2, and LSD1/KDM1A, alongside other transcriptional and stress‑response nodes (for example EP300, SOX9, NANOG, TFEB, TFAM). That overlaps conceptually with the same programmes often active in **FGFR1-driven EMT and fibrosis biology.** It is not yet proof that melatonin directly targets FGFR1 amplification in patients. {% hint style="info" %} For liposomal delivery context, see [DIY Liposomal Melatonin](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/diy-liposomal-melatonin.md) in the [Liposomal Encapsulation of Anti-cancer Compounds](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds.md) hub. {% endhint %}
Key fibrotic condensate nodes in the 26-gene set Several proteins in [Loh’s condensate framework](https://www.biorxiv.org/content/10.64898/2026.02.03.703596v1) sit directly on the fibrosis and EMT axis. **SMAD3** is the clearest example. It is a canonical [**TGF-beta** effector in fibrosis](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1649179/full). It drives transcription of **collagen**, **fibronectin**, and other extracellular-matrix genes. In Loh’s model, it also sits inside active nuclear hubs that help lock in fibrotic programmes. **TWIST1** is a core EMT factor. It pushes cells toward a more mesenchymal, invasive, matrix-remodelling state, which fits the broader [EMT-fibrosis overlap](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.607483/full). That makes it relevant to both metastatic escape and desmoplastic tumour behaviour. **VIM** is more than a marker. It supports the mechanics of mesenchymal transition and fibroblast-like cell behaviour in the same [EMT-associated programme](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.607483/full). That matters in stiffer, more invasive, fibrosis-rich tumour settings. **YAP1** and **TAZ** are major mechanosensitive co-activators. They help translate matrix stiffness into transcription. That links them directly to **CAF activation**, tissue stiffening, and extracellular-matrix deposition, while Loh places them inside [condensate-linked oncogenic hubs](https://www.biorxiv.org/content/10.64898/2026.02.03.703596v1). **CTNNB1** or **beta-catenin** adds a second major fibrosis route. It cooperates with **TGF-beta** and **YAP/TAZ** in [EMT and fibroblast activation](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.607483/full). That makes it relevant where stromal remodelling and endocrine escape overlap. **EZH2** and **KDM1A/LSD1** sit on the epigenetic side. They help stabilise resistant and fibrogenic gene-expression states, and Loh includes them in [Axis I condensate-linked control](https://www.biorxiv.org/content/10.64898/2026.02.03.703596v1). That matters if the question is not just signalling, but how a fibrotic programme becomes persistent. **EGFR** is less fibrosis-specific on its own. It still interacts with [EMT-linked signalling networks](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.607483/full) in ways that can reinforce invasion and stromal activation. Taken together, **SMAD3, TWIST1, VIM, YAP1, TAZ, CTNNB1, EZH2, KDM1A, and EGFR** are the main condensate-linked melatonin targets with the clearest overlap with fibrotic and desmoplastic biology.
How melatonin’s anti-fibrotic literature lines up with those targets The broader melatonin literature lines up well with those same nodes. Across organ-fibrosis and tumour-fibrosis models, melatonin repeatedly shows pressure against [**TGF-beta/SMAD3** signalling](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1649179/full). That usually means less **SMAD3** activation, less nuclear fibrotic drive, and lower extracellular-matrix output. Melatonin also repeatedly shows [**anti-EMT** behaviour](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.607483/full). That includes pressure against factors such as **TWIST1** and **VIM**, alongside preservation of more epithelial features. That matters because EMT and fibrosis often travel together in resistant **ER-positive** disease. The same logic extends to **YAP/TAZ** and **beta-catenin**. The literature there is less tidy, but the direction is similar. Melatonin often looks anti-mechanosensitive, anti-stiffness, and anti-remodelling. The epigenetic layer also fits. If melatonin lowers condensate stability around **EZH2** and **LSD1/KDM1A** in [Loh’s model](https://www.biorxiv.org/content/10.64898/2026.02.03.703596v1), it could weaken the transcriptional memory that keeps fibrotic and resistant states locked in place. That is still a research model. It is not yet a validated clinical mechanism. Even so, Loh’s framework gives a useful structural explanation for something the broader melatonin literature already suggests. Melatonin may not need to target fibrosis through one single pathway. It may instead destabilise several linked hubs at once around **SMAD3**, **YAP/TAZ**, **beta-catenin**, **TWIST1**, and related EMT-stromal programmes. That same direction also fits breast-stromal data showing melatonin can reduce local estrogen-supportive signalling in [breast-cancer-associated fibroblasts](https://jmsgr.tamhsc.edu/melatonin-inhibits-estrogen-production-in-er%CE%B1-breast-cancer-associated-fibroblasts-and-counteracts-tamoxifen-resistance/). That is exactly the kind of overlap that makes melatonin biologically interesting in **FGFR1-amplified**, **EMT-leaning**, or fibrosis-rich **ER-positive** disease.
### Honokiol **Honokiol** is a biphenolic compound from Magnolia bark with preclinical anti‑cancer activity across several tumour types. In lung squamous cell carcinoma models, honokiol induced apoptosis, cell‑cycle arrest, and reduced migration while down‑regulating FGF2 and FGFR1 activation, and it suppressed growth of FGFR1‑driven xenografts by interrupting the FGF2–FGFR1 autocrine loop. In breast‑cancer models, honokiol inhibits epithelial–mesenchymal transition, migration, and invasion via effects on Stat3/ZEB1/E‑cadherin signalling and EMT‑associated transcription factors, and it can sensitise breast‑cancer cells to TNF‑α‑induced apoptosis and leptin‑driven progression. Human evidence specific to **FGFR1‑amplified ER‑positive breast cancer** is not established; honokiol should be considered an experimental adjunct with plausible relevance to FGFR1 signalling, EMT, and invasion based on preclinical work, not a validated targeted therapy in this setting. ### Bottom line FGFR1 amplification is a meaningful finding in **ER-positive, HER2-negative breast cancer**. It most strongly points toward **endocrine resistance pressure** and more aggressive **luminal-B-like biology**. If the signal fluctuates on **Guardant360**, the safest interpretation is usually **changing ctDNA visibility**, not proof that the biology was fake or permanently gone. FGFR1 remains a **real research target**, but not a routine standard-of-care target in breast cancer today. {% hint style="info" %} This page stays focused on t**he driver layer of FGFR in** **ER-positive breast cancer**. For the broader cross-cancer framing of very hard, stiff, or “cement-like” lesions, including the three-layer model of driver programme, fibrotic scaffold, and fibrin/perfusion, see [Fibrotic, Hard or “Cement‑Like” Lesions](/myhealingcommunity-docs/fibrotic-hard-or-cement-like-lesions.md). {% endhint %}

Go to the ER+/HER2- Breast Cancer Hub Overview/Directory Page

### Key references * FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive breast cancer\ * Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer\ * FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer\ * Association of FGFR1 with ERalpha Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer\ * Future perspectives: targeting fibroblast growth factor receptor 1 in cancer\ * Pharmacological and Biological Targeting of FGFR1 in Cancer\ * FGFR1 Amplification — OncoKB\ * The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrosis and Cancer\ * Dwairy M et al., Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy —

Return to the A–Z directory of
evidence-based research summaries and
practical support resources

Go to Home

*** {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/fgfr1-amplification-in-er+-breast-cancer.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.